about
Guanylate cyclase stimulators for pulmonary hypertensionRole of Biomarkers in the Diagnosis, Risk Assessment, and Management of Pulmonary HypertensionOptimal management of pulmonary arterial hypertension: prognostic indicators to determine treatment courseTreatment-related biomarkers in pulmonary hypertensionCirculating Angiopoietin-1 Is Not a Biomarker of Disease Severity or Prognosis in Pulmonary HypertensionNovel biomarkers for risk stratification in pulmonary arterial hypertensionHemodynamic effects of ambrisentan-tadalafil combination therapy on progressive portopulmonary hypertension.SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension.Follow-up tricuspid annular plane systolic excursion predicts survival in pulmonary arterial hypertension.Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel reportAre hemodynamics surrogate end points in pulmonary arterial hypertension?Triggering the succinate receptor GPR91 enhances pressure overload-induced right ventricular hypertrophy.H2 receptor antagonists and right ventricular morphology: the MESA right ventricle studyN-terminal pro-brain natriuretic peptide is a useful prognostic marker in patients with pre-capillary pulmonary hypertension and renal insufficiency.Current clinical management of pulmonary arterial hypertensionNon-Invasive Determination of Cardiac Output in Pre-Capillary Pulmonary Hypertension.Automatic segmentation and analysis of the main pulmonary artery on standard post-contrast CT studies using iterative erosion and dilation.Effects of ranolazine on exercise capacity, right ventricular indices, and hemodynamic characteristics in pulmonary arterial hypertension: a pilot studyCase report: a patient with pulmonary arterial hypertension transitioning from a PDE-5 inhibitor to Riociguat.Old medications and new targeted therapies in systemic sclerosis.Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHINEarly Observations on the Use of Riociguat in a Large, Metropolitan Pulmonary Arterial Hypertension/Chronic Thromboembolic Pulmonary Hypertension Treatment Center.Prognostic Significance of Biomarkers in Pulmonary Arterial Hypertension.Health-related Quality of Life and Survival in Pulmonary Arterial Hypertension.The quest for biomarker discovery in pulmonary arterial hypertension: the right takes lessons from the leftReduced immunoreactivities of B-type natriuretic peptide in pulmonary arterial hypertension rats after ranolazine treatmentPrevalence of Sodium and Fluid Restriction Recommendations for Patients with Pulmonary HypertensionBaseline Characteristics and Risk Factors of Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus Patients.Physical and functional follow-up of tuberculosis patients in initial intensive phase of treatment in Cameroon using the 6-min walk test.Relevance of angiopoietin-2 and soluble P-selectin levels in patients with pulmonary arterial hypertension receiving combination therapy with oral treprostinil: a FREEDOM-C2 biomarker substudy.Six-minute walk test in pulmonary arterial hypertensionCurrent and advancing treatments for pulmonary arterial hypertension in childhood.Biomarkers in pulmonary arterial hypertension.Early detection of pulmonary arterial hypertension.Pharmacokinetic and pharmacodynamic evaluation of macitentan , a novel endothelin receptor antagonist for the treatment of pulmonary arterial hypertension.Predicting the Need for Upfront Combination Therapy in Pulmonary Arterial Hypertension.Treating pulmonary hypertension in pediatrics.Perioperative management of patients with pulmonary hypertension for non-cardiac surgery.What's new in the treatment of portopulmonary hypertension?Biomarkers and prognostic indicators in pulmonary arterial hypertension.
P2860
Q26470534-FBF4D0B7-B0A5-4F00-B023-5A52C04E546FQ26744186-706F48DE-0D61-4549-B9D4-E6BC7361414EQ27023074-5E6DCAAE-A415-4386-8313-CF7E67A8177EQ28081276-9F6FF54F-5510-4E50-86D1-2CCB6D3271CCQ28109687-9BA8E5CE-416A-4E2F-B629-42C174B88976Q28596829-2FE97142-61FA-44B2-B81C-866B1A33BC8FQ33418891-1A6BE71E-4D83-4B09-8780-3B33E72E425EQ33589653-825796C4-EF0D-44AA-A73D-E49772E9392AQ33788434-E4D08984-756E-4EAC-96AE-038FDA8193B2Q34064492-93BB7699-8BAC-49B5-904C-08B68B92F916Q34098418-49D277A5-B60F-409F-82B8-D1A997F772EAQ34371092-94DA99FC-8191-4AB5-9863-2BE83C55CE53Q34984706-CE12FB8E-8397-4DA4-A744-0708D4C089F9Q35153971-D1CE14CD-9E62-4BB1-B9E5-AAD8B6BA25E4Q35673783-447CB363-0DFA-41B6-A23A-C4B4C9E0D65FQ35726725-05EAF9B5-C1D3-42E4-A045-A079B0C96E18Q35789645-72D7FEB4-9CDC-4E09-A449-9A604D21B22FQ36016535-05A8350E-4A04-4A77-B7FA-5AB99BC47E7AQ36021594-AD06330D-F7B6-48A4-9F14-A2EA063EB7C4Q36154430-1B6D1F7E-9F2B-4E41-93A8-028D615EE3D4Q36332690-C8583C75-C78D-419A-AC5E-64134AB508BCQ36363156-0847B850-E57E-4682-9AA9-ECE6BAA27E4BQ36490165-0ED2208E-E62D-419E-BD3D-A3229C5382C4Q36490169-D8853FDC-EE53-4298-94C8-A74FFFE0B9B8Q36593457-7872063D-D046-4E27-8852-BCE078F16C94Q36760329-36357315-DFCD-484E-9066-09A3BED7ED4EQ37081642-5D654E99-F733-4574-BF29-A95BC041FB23Q37206944-F0C6ED44-24B3-4CD4-BE3D-FA0C358F3008Q37272911-A00D4B43-4D29-4F8B-9BF6-1B4CE3085D2BQ37555376-6659291A-04F7-4E3E-99C7-E2F1B013054CQ37680689-F148708D-80A9-44B5-946C-0363F4A6C69AQ38232339-A102EE03-B846-4953-AC6C-E49ED0D91D3EQ38251298-D3CC3E59-D387-4B10-9DEC-1533ABBD907EQ38271027-2ACD0B65-0EF8-4C94-99E8-8F434354158DQ38325919-644D7A12-7FE7-429C-BC28-C59F074C6360Q38329154-F74C4696-1D4C-43BD-881D-72CC35B6B94AQ38349395-FC1D43FD-71BA-42E5-8342-8C04EE6D0B0AQ38367774-98947296-8738-4C8E-B3B8-1FF4985C95B0Q38424573-DDCF53AD-3DC1-44BF-AC4F-0351A81A1C78Q38520683-C79596D5-E0F2-46C9-AABD-861F57B6CA0B
P2860
description
2013 nî lūn-bûn
@nan
2013 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Treatment goals of pulmonary hypertension
@ast
Treatment goals of pulmonary hypertension
@en
Treatment goals of pulmonary hypertension
@nl
type
label
Treatment goals of pulmonary hypertension
@ast
Treatment goals of pulmonary hypertension
@en
Treatment goals of pulmonary hypertension
@nl
prefLabel
Treatment goals of pulmonary hypertension
@ast
Treatment goals of pulmonary hypertension
@en
Treatment goals of pulmonary hypertension
@nl
P2093
P50
P3181
P1476
Treatment goals of pulmonary hypertension
@en
P2093
Hanno H Leuchte
Michael A Mathier
Myung H Park
Sanjay Mehta
Vallerie V McLaughlin
Victor F Tapson
P304
P3181
P356
10.1016/J.JACC.2013.10.034
P407
P433
P577
2013-12-24T00:00:00Z